Amgen Inc - Free Cash Flow To Equity

Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Free-Cash-Flow-To-Equity" stands at 6.54 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 03/31/2024.

Amgen Inc's third quarter result of 2.75 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 201.65 percent compared to it's second quarter result.

Also, Amgen Inc's third quarter result of 2.75 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 146.68 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 6.54 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 33.31 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 109.65 percent compared to the value the year prior.
The 1 year change in percent is 109.65.
The 3 year change in percent is -43.07.
The 5 year change in percent is -58.78.
The 10 year change in percent is -15.56.

The Serie's long term average value is 11.81 Billion United States Dollars. It's latest available value, on 09/30/2025, is 44.62 percent lower, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 06/30/2024, to it's latest available value, on 09/30/2025, is +339.74%.
The Serie's change in percent from it's maximum value, on 06/30/2023, to it's latest available value, on 09/30/2025, is -81.32%.